Trials / Completed
CompletedNCT03651102
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia
Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 654 (actual)
- Sponsor
- Blood Diseases Clinic · Academic / Other
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g. Crohn's disease) and skin disorders (e.g. leprosy). Thalidomide has been successfully used in adult thalassemia patients. The current study explores its role in transfusion-dependent thalassemia patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide and Hydroxyurea | Dosage: Thalidomide 1-4mg/kg/day, Hydroxyurea 10-20mg/kg/day |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2021-11-30
- Completion
- 2022-03-01
- First posted
- 2018-08-29
- Last updated
- 2022-03-25
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT03651102. Inclusion in this directory is not an endorsement.